TY - JOUR
T1 - Atrial fibrillation with a focus on oral antiarrhythmic therapy
AU - von Vital, Jacqueline M.
AU - Deeugenio, Deborah L.
AU - Jackson, Anna Wodlinger
AU - Kiernan, Thomas
AU - Ruggiero, Nicholas J.
PY - 2011
Y1 - 2011
N2 - Atrial fibrillation (AF) is considered the most common sustained arrhythmia resulting in significant morbidity, mortality, and cost. Management of AF includes rate control, prevention of thrombosis, and, in some patients, conversion and maintenance of normal sinus rhythm. Pharmacologic therapy is often used for maintenance of normal sinus rhythm. Current recommended antiarrhythmic drugs include dofetilide, propafenone, sotalol, and amiodarone. In March 2009 a new antiarrhythmic, dronedarone, was approved for use in patients with atrial fibrillation. The aim of this article is to review primary literature of currently available oral antiarrhythmic agents for efficacy, safety and place in therapy in the treatment of atrial fibrillation.
AB - Atrial fibrillation (AF) is considered the most common sustained arrhythmia resulting in significant morbidity, mortality, and cost. Management of AF includes rate control, prevention of thrombosis, and, in some patients, conversion and maintenance of normal sinus rhythm. Pharmacologic therapy is often used for maintenance of normal sinus rhythm. Current recommended antiarrhythmic drugs include dofetilide, propafenone, sotalol, and amiodarone. In March 2009 a new antiarrhythmic, dronedarone, was approved for use in patients with atrial fibrillation. The aim of this article is to review primary literature of currently available oral antiarrhythmic agents for efficacy, safety and place in therapy in the treatment of atrial fibrillation.
KW - Amiodarone
KW - Antiarrhythmics
KW - Atrial fibrillation
KW - Cardioversion
KW - Dronedarone
KW - Rate control
KW - Rhythm
UR - http://www.scopus.com/inward/record.url?scp=78650966916&partnerID=8YFLogxK
U2 - 10.2174/157488511794079022
DO - 10.2174/157488511794079022
M3 - Article
AN - SCOPUS:78650966916
SN - 1574-8855
VL - 6
SP - 65
EP - 78
JO - Current Drug Therapy
JF - Current Drug Therapy
IS - 1
ER -